GLPwatch
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT00039013 · Completed
Last updated 2026-05-28This clinical trial tested the medication AC2993 in adults with type 2 diabetes who were already taking metformin to see how it affects blood sugar control over 30 weeks.
What this study is testing ClinicalTrials.gov NCT00039013 ↗
Description as written by the study sponsor.
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (metformin) throughout the study.
Treatments tested
- AC2993 also known as synthetic exendin-4 Drug
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
- AC2993 also known as synthetic exendin-4 Drug
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
- Placebo Drug
Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
- Placebo Drug
Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
| Main thing measured | Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30) |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00039013 ↗